[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Cytrellis Biosystems, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":102},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100610230","ellacor-micro-coring-technology-in-fitzpatrick-skin-types-i-vi-including-patients-receiving-glucagon-like-peptide-1-receptor-agonists-100610230",false,"NCT07224880","Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists","Safety and Outcomes of Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs): A Case Series","Inclusion Criteria:\n\n1. Male and female adult, between the ages of 30 and 65\n2. Fitzpatrick Skin Type I-VI\n3. Have moderate to severe wrinkles on the mid and lower face, according to Lemperle Wrinkle Severity Scale (LWSS), i.e. score 3, 4 or 5.\n4. Have moderate to extreme abdominal laxity according to Stokes Scale (i.e., score of 2-4 on a scale of 0-4).\n5. Willingness to sign Informed Consent Form\n\nExclusion Criteria:\n\n1. Pregnant women or nursing mothers\n2. Patients with dermatosis, open wounds, sores, or irritated skin in the treatment area\n3. Patients with allergy to stainless steel or to topical, oral, or injected medications or preparations that may be used during the procedure, such as petrolatum, lidocaine, bupivacaine, chlorhexidine, or povidone-iodine\n4. Patients with a history or presence of any clinically significant bleeding disorder\n5. Patients with dermatological or autoimmune conditions that may affect the treatment outcome; these may include, but are not limited to: actinic keratosis, raised nevi, rosacea, melasma, active acne, cutaneous papules\u002Fnodules, active inflammatory lesions, dermatitis, psoriasis, cellulitis, urticarial folliculitis, acute inflammatory phase of scleroderma, rheumatoid arthritis, eczema, psoriasis, allergic dermatitis, collagen disorders, or lupus\n6. Patients with systemic infections or acute local skin infections (as Hepatitis disorders type A, B, C, D, E or F or HIV infection)\n7. Patients who are on a high dose of anti-coagulants or blood-thinning substances, e.g., aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, heparin, acetylsalicylic acid during the previous fourteen (14) days\n8. Patients who are on courses of chemotherapy, high-dose corticosteroid use, or radiation in the treatment area\n9. Patients with have undergone plastic surgery of the face within the last twelve (12) months or have any facial surgical scars less than twelve (12) months old\n10. Patients who have undergone injections of dermal fillers, fat, or botulinum toxin, as well as any minimally invasive\u002Finvasive skin treatment in the treatment area during the previous six (6) months\n11. Patients with scars less than six (6) months old in the treatment area","ALL","30 Years","65 Years",{"count":20,"type":21},10,"ESTIMATED","OBSERVATIONAL","The main purpose of the study is to collect information about how the device functions in a variety of treatment areas and skin types and to find out what changes, if any, occur in the skin treated with the study device compared to the skin that wasn't treated including patients receiving GLP-1's, a class of medications that mimic a natural hormone to help control blood sugar and support weight loss. The study will also evaluate side effects that occur with this treatment, if any. Standardized 2D Imaging will be used to quantify reduction of wrinkle severity",[25,26,27],"glp1 Agonist","Gene Expression","Skin Laxity",[29,30,31],"ellacor","GLP-1","weight loss","RECRUITING","2025-12-30",{"date":35,"type":36},"2025-12-31","ACTUAL",{"date":38,"type":36},"2025-10-14",{"date":40,"type":21},"2026-02-28",{"name":42,"class":43},"Cytrellis Biosystems, Inc.","INDUSTRY",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100346639","study-to-evaluate-the-safety-and-efficacy-of-the-cytrellis-micro-coring-device-for-the-treatment-of-moderate-to-severe-facial-wrinkles-100346639","NCT03793348","Study to Evaluate the Safety and Efficacy of the Cytrellis Micro-Coring Device for the Treatment of Moderate to Severe Facial Wrinkles","A Prospective, Multi-center, Pivotal Study to Evaluate the Safety and Efficacy of the Cytrellis Micro-Coring Device for the Treatment of Moderate to Severe Facial Wrinkles","Inclusion Criteria:\n\n* Males and females 40-70 years of age\n* Fitzpatrick Skin Type I to IV as judged by the Investigator\n* Cheek areas are at least a score of 3 using the Lemperle Wrinkle Assessment Scale as judged by the Investigator\n* Able to provide written informed consent, understand and willing to comply with all study related procedures and follow-up visits.\n\nExclusion Criteria:\n\n* Lesions suspicious for any malignancy or the presence of actinic keratosis, melasma, vitiligo, cutaneous papules\u002Fnodules or active inflammatory lesions in the areas to be treated\n* History of keloid formation or hypertrophic scarring\n* History of trauma or surgery to the treatment areas in the past 6 months\n* Scar present in the areas to be treated\n* Silicone injections in the areas to be treated\n* Injection of dermal fillers, fat or botulinum toxin, as well as any minimally invasive\u002Finvasive medical device for skin treatment, in the study treatment areas, within the past 6 months (i.e., dermabrasion, laser, RF devices)\n* Active smokers (0.5 pack\u002Fday) or having quit within 3 months prior to treatment\n* Active, chronic, or recurrent infection\n* History of compromised immune system or currently being treated with immunosuppressive agents\n* History of sensitivity to analgesic agents, Aquaphor®, topical or local anesthetics (e.g., lidocaine, benzocaine, procaine) or chlorhexidine, povidone-iodine or epinephrine\n* Excessive sun exposure and use of tanning beds or tanning creams within 30 days prior to treatment\n* Treatment with aspirin or other blood thinning agents within 14 days prior to treatment\n* History or presence of any clinically significant bleeding disorder\n* Any issue that, at the discretion of the Investigator, would interfere with assessment of safety or efficacy or compromise the subject's ability to participate in the study\n* Treatment with an investigational device or agent within 30 days before treatment or during the study period",true,"40 Years","70 Years",{"count":56,"type":21},35,"INTERVENTIONAL",[59],"NA","Study evaluating the efficacy of a micro coring device for the treatment of moderate to severe check wrinkles",[62],"Wrinkle",[64,65,66],"facial wrinkles","skin laxity","sagging skin","2019-01-02",{"date":69,"type":36},"2019-01-04",{"date":71,"type":36},"2018-11-12",{"date":73,"type":21},"2019-08-21",{"name":42,"class":43},6,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":52,"sex":16,"minAge":83,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":57,"phases":86,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":44},"100345771","study-to-evaluate-the-efficacy-of-a-micro-coring-device-for-the-treatment-of-scars-of-the-cytrellis-micro-coring-device-for-the-treatment-of-scars-100345771","NCT03782038","Study to Evaluate the Efficacy of a Micro Coring Device for the Treatment of Scars of the Cytrellis Micro-Coring Device for the Treatment of Scars","A Prospective, Multi-center, Pilot Study to Evaluate the Safety and Efficacy of the Cytrellis Micro-Coring Device for the Treatment of Scars","Inclusion Criteria:\n\n* 18 years of age or older\n* Fitzpatrick scale I-VI.\n* Any type of scar except for keloid scars\n* Able to provide written informed consent, understand and willing to comply with study related procedures and follow-ups.\n\nExclusion Criteria:\n\n* Previous treatment of the scar tissue within last 6 months.\n* Silicone, fat, collagen or synthetic material in the treatment area.\n* History of keloid formation.\n* Active smokers (smoking more than ½ pack per day) or having quit smoking (½ pack per day) for less than 3 months.\n* Active, chronic, or recurrent infection.\n* Compromised immune system (e.g. diabetes).\n* Hypersensitivity to analgesic agents.\n* Co-morbid condition that could limit ability to participate in the study or to comply with follow-up requirements.\n* Pregnant or breastfeeding.\n* Any issue that, at the discretion of the investigator, would contra-indicate the subject's participation.\n* Any medication that may cause bleeding such as anticoagulants.\n* Allergy to lidocaine and\u002For epinephrine","18 Years",{"count":85,"type":21},30,[59],"A study to evaluate the safety and effectiveness of a micro coring device for the treatment of scars.",[89],"Scars",[91,92,93],"Acne Scars","Stretchmarks","Surgical Scars","2018-12-19",{"date":96,"type":36},"2018-12-21",{"date":98,"type":36},"2018-09-13",{"date":100,"type":21},"2019-11-21",{"name":42,"class":43},""]